Overview

Phase 3 Study of SNF472 for Calciphylaxis

Status:
Recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

The primary objectives are to assess the efficacy, safety, and tolerability of SNF472 compared to placebo when added to background care for the treatment of calciphylaxis (CUA).

Phase:

Phase 3

Details

Lead Sponsor:

Sanifit Therapeutics S. A.